Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAMPT | P43490 | 5/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | FES | P07332 | 1/20 | 0.47 |
| ▸ | RET | P07949 | 1/20 | 0.47 |
| ▸ | MARK3 | P27448 | 1/20 | 0.47 |
| ▸ | TYK2 | P29597 | 1/20 | 0.47 |
| ▸ | FLT4 | P35916 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.47 |
| ▸ | CLK2 | P49760 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | PTAFR | P25105 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL81910 | 0.90 | PTAFR (0.50) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL82430 | 0.89 | PTAFR (0.49) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL81394 | 0.89 | PTAFR (0.49) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL82722 | 0.88 | PTAFR (0.56) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL3079286 | 0.88 | PTAFR (0.48) | NAMPTCYP3A4CYP2C9LMNAPTAFR | |
| SCHEMBL83930 | 0.87 | LMNA (0.49) | CYP3A4CYP2C9LMNAPTAFRALDH1A1 | |
| SCHEMBL5558257 | 0.86 | CDK2 (0.57) | NAMPTCYP3A4CYP2C9FLT4CCR3 | |
| SCHEMBL3080363 | 0.85 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9C3AR1CHRM4 | |
| SCHEMBL5557428 | 0.85 | DRD2 (0.48) | CYP3A4CYP2C9LMNAPTAFRALDH1A1 | |
| SCHEMBL3073763 | 0.84 | NAMPT (0.45) | NAMPTCYP3A4CYP2C9CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | claimed |
| US-6506572-B2 | Inhibitor of niacinamide phosphoribosyl transferase (NAPRT) | KLINGE PHARMA GMBH (DE) | 2003-01-14 | — | — | US | claimed |
| JP-2002537380-A | — | — | 2002-11-05 | — | — | JP | claimed |
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | KLINGE PHARMA GMBH | 2002-10-31 | — | — | US | claimed |
| EP-1154998-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | Klinge Pharma GmbH (DE) | 2001-11-21 | — | — | EP | claimed |
| WO-2000050399-A1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | KLINGE PHARMA GMBH (DE) | 2000-08-31 | — | — | WO | claimed |
| EP-1031564-A1 | Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy | Klinge Pharma GmbH (DE) | 2000-08-30 | — | — | EP | claimed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1154998-B1 | INHIBITORS OF CELLULAR NIACINAMIDE MONONUCLEOTIDE FORMATION AND THEIR USE IN CANCER THERAPY | ASTELLAS DEUTSCHLAND GMBH (DE) | 2007-09-26 | — | — | EP | disclosed |
| EP-1816124-A2 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | Astellas Deutschland GmbH (DE) | 2007-08-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020160968-A1 | Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy | NAMPT, NAPRT, NNT | NAMPT 1/4885CYP3A4 1746/4885CYP2C9 1567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.